{"id":"combination-with-somatostatin-analogue-octreotide","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Gallstone formation (cholelithiasis)"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL3350724","moleculeType":"Small molecule","molecularWeight":"1356.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Octreotide mimics the action of endogenous somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells and tumors. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, and also has direct antiproliferative effects on neuroendocrine tumor cells. When used in combination therapy, it may enhance therapeutic efficacy by reducing hormone-driven tumor growth and associated symptoms.","oneSentence":"Octreotide is a somatostatin analogue that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:43:37.930Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors)"},{"name":"Acromegaly"},{"name":"Variceal bleeding in portal hypertension"}]},"trialDetails":[{"nctId":"NCT02795858","phase":"PHASE2","title":"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-06-14","conditions":"Carcinoid Tumors","enrollment":43},{"nctId":"NCT05359146","phase":"EARLY_PHASE1","title":"Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-28","conditions":"Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)","enrollment":16},{"nctId":"NCT02685709","phase":"PHASE3","title":"Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly","status":"COMPLETED","sponsor":"Chiasma, Inc.","startDate":"2016-02","conditions":"Acromegaly","enrollment":146},{"nctId":"NCT00376064","phase":"PHASE4","title":"Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":"Acromegaly","enrollment":20},{"nctId":"NCT01755182","phase":"PHASE3","title":"Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors","status":"TERMINATED","sponsor":"National Cancer Institute, Naples","startDate":"2013-07","conditions":"Neuroendocrine Tumors","enrollment":1},{"nctId":"NCT01203306","phase":"PHASE2","title":"Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2006-01","conditions":"Neuroendocrine Carcinomas","enrollment":42},{"nctId":"NCT00595140","phase":"PHASE4","title":"Acute Application of Pegvisomant and Octreotide in Acromegaly","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2008-01","conditions":"Acromegaly","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":77,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Octreotide: Sandostatin 100µg: MA number 29423.01.00"],"phase":"marketed","status":"active","brandName":"combination with somatostatin analogue octreotide","genericName":"combination with somatostatin analogue octreotide","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Octreotide is a somatostatin analogue that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors. Used for Neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors), Acromegaly, Variceal bleeding in portal hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}